Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate if concentration of tacrolimus metabolites is increased in patients presenting tacrolimus (TAC) side effects.
The study will evaluate whether the blood concentration of TAC metabolites (13-O-desmethyl-tacrolimus, 15-O-desmethyl-tacrolimus and 31-O-desmethyl-tacrolimus), measured between Day1 and Day5 of its introduction, is increased in patients with TAC toxicity. A blood test will be performed daily from Day1 to Day5 for the measurement of TAC concentration and TAC metabolites concentration.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
CHU Rennes
Rennes, France
Start Date
May 8, 2022
Primary Completion Date
June 8, 2024
Completion Date
June 8, 2024
Last Updated
July 28, 2023
48
ESTIMATED participants
Lead Sponsor
Rennes University Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions